Close Menu

Colorectal Cancer

News and reporting on colorectal cancer.

The St. Louis-based firm will use the funds to develop its colorectal cancer screening test, which measures eukaryotic RNA isolated from epithelial cells in stool.

According to Natera CEO Steve Chapman, the agreement will not detract from Natera's own efforts to establish its exome sequencing-based Signatera assay.

The Netherlands-based biotech firm will use the funding to develop a group of biomarkers to detect colorectal cancer.

The agency has approved the use of Exact's Cologuard test for average-risk individuals aged 45 and older.

Startup BioLizard will develop the algorithm to help Novigenix migrate its immuno-transcriptiomic assay for early colorectal cancer detection to a new NGS-based platform.

The study said that Cologuard was an "inefficient screening option" for colorectal cancer given its cost as compared to other CRC screening methods.

The team analyzed multigene panel test data from Ambry Genetics for 165,000 individuals, focusing on hereditary cancer risk related to 32 genes in six cancer types.

The Belgian oncology molecular diagnostics firm reported a 17 percent increase in product sales but said that sales of cartridges in the US were lower than expected. 

In Genome Biology this week: analysis of colorectal cancer progression, secretion system used by Vibrio cholerae, and more.

The German company's new Genome Enhancer product is an adaptation of its flagship multi-omics software for clinicians and biologists without bioinformatics expertise.

Pages

The Atlantic reports another SARS-CoV-2 testing problem may be lurking: backlogs.

Researchers have sequenced the genome of "the Methuselah of freshwater fish."

The US Biomedical Advanced Research and Development Authority is supporting efforts to develop vaccines against SARS-CoV-2.

In Genome Biology this week: difference in methylation in neurons from Parkinson's disease patients, differential expression analysis by barcoded sequencing approach, and more.